126 related articles for article (PubMed ID: 19497974)
1. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice.
Iakoubov R; Lauffer LM; Trivedi S; Kim YI; Brubaker PL
Endocrinology; 2009 Sep; 150(9):4033-43. PubMed ID: 19497974
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.
Trivedi S; Wiber SC; El-Zimaity HM; Brubaker PL
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G840-9. PubMed ID: 22323126
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
4. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion.
Rowland KJ; Trivedi S; Lee D; Wan K; Kulkarni RN; Holzenberger M; Brubaker PL
Gastroenterology; 2011 Dec; 141(6):2166-2175.e7. PubMed ID: 21925122
[TBL] [Abstract][Full Text] [Related]
5. The "cryptic" mechanism of action of glucagon-like peptide-2.
Rowland KJ; Brubaker PL
Am J Physiol Gastrointest Liver Physiol; 2011 Jul; 301(1):G1-8. PubMed ID: 21527727
[TBL] [Abstract][Full Text] [Related]
6. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.
McDonagh SC; Lee J; Izzo A; Brubaker PL
Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G461-8. PubMed ID: 17585017
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes in the intestinal growth promoting effects of glucagon-like peptide 2 following intestinal resection.
Kaji T; Tanaka H; Redstone H; Wallace LE; Holst JJ; Sigalet DL
J Surg Res; 2009 Apr; 152(2):271-80. PubMed ID: 19062041
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-2 Requires a Full Complement of Bmi-1 for Its Proliferative Effects in the Murine Small Intestine.
Smither BR; Pang HY; Brubaker PL
Endocrinology; 2016 Jul; 157(7):2660-70. PubMed ID: 27187177
[TBL] [Abstract][Full Text] [Related]
9. The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function.
Dong CX; Zhao W; Solomon C; Rowland KJ; Ackerley C; Robine S; Holzenberger M; Gonska T; Brubaker PL
Endocrinology; 2014 Feb; 155(2):370-9. PubMed ID: 24265452
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 2 therapy reduces negative effects of diarrhea on calf gut.
Connor EE; Kahl S; Elsasser TH; Baldwin RL; Fayer R; Santin-Duran M; Sample GL; Evock-Clover CM
J Dairy Sci; 2013 Mar; 96(3):1793-802. PubMed ID: 23312992
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice.
Hartmann B; Thulesen J; Kissow H; Thulesen S; Orskov C; Ropke C; Poulsen SS; Holst JJ
Endocrinology; 2000 Nov; 141(11):4013-20. PubMed ID: 11089531
[TBL] [Abstract][Full Text] [Related]
12. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
Dubé PE; Forse CL; Bahrami J; Brubaker PL
Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome.
Martin GR; Wallace LE; Sigalet DL
Am J Physiol Gastrointest Liver Physiol; 2004 Jun; 286(6):G964-72. PubMed ID: 14962847
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs.
Sigalet DL; de Heuvel E; Wallace L; Bulloch E; Turner J; Wales PW; Nation P; Wizzard PR; Hartmann B; Assad M; Holst JJ
Regul Pept; 2014 Jan; 188():70-80. PubMed ID: 24368164
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
Thulesen J; Hartmann B; Hare KJ; Kissow H; Ørskov C; Holst JJ; Poulsen SS
Gut; 2004 Aug; 53(8):1145-50. PubMed ID: 15247183
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.
Dubé PE; Rowland KJ; Brubaker PL
Endocrinology; 2008 Jan; 149(1):291-301. PubMed ID: 17884945
[TBL] [Abstract][Full Text] [Related]
17. Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.
Yusta B; Holland D; Waschek JA; Drucker DJ
Endocrinology; 2012 Jun; 153(6):2623-32. PubMed ID: 22535770
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.
Anini Y; Izzo A; Oudit GY; Backx PH; Brubaker PL
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1599-606. PubMed ID: 17284578
[TBL] [Abstract][Full Text] [Related]
19. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.
Hare KJ; Hartmann B; Kissow H; Holst JJ; Poulsen SS
Clin Cancer Res; 2007 Sep; 13(17):5170-5. PubMed ID: 17785573
[TBL] [Abstract][Full Text] [Related]
20. Exogenous GLP-2 and IGF-I induce a differential intestinal response in IGF binding protein-3 and -5 double knockout mice.
Murali SG; Brinkman AS; Solverson P; Pun W; Pintar JE; Ney DM
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G794-804. PubMed ID: 22281475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
